Clinical trial · Interventional
Advanced Therapeutics in Rheumatoid Arthritis (RA)
NCT03976245CI-TRIAL-00083125recruitingPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will evaluate the retention rates of two advanced therapies, Tumour Necrosis Factor (TNF) and Janus kinase inhibitor (JAK) in the treatment of adults with Rheumatoid Arthritis (RA) over a two year period. It will also examine the ability to embed a clinical trial in a clinical situation using an electronic medical record (EMR).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Rheumatoid Arthritis | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Etanercept | Drug | — | UNRESOLVED |
| tofacitinib | Drug | Tofacitinib | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- etanercept
- description
- etanercept 50 mg subcutaneously injected per week
- interventionNames
- Drug: Etanercept
- type
- ACTIVE_COMPARATOR
- label
- tofacitinib
- description
- tofacitinib 5 mg orally daily
- interventionNames
- Drug: tofacitinib
Primary outcomes (1)
- measure
- Retention Rates
- timeFrame
- 24 months
- description
- Evaluation of the proportion of patients in each arm still on the randomized treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patients with RA who meet criteria for obtaining an advanced therapeutic through usual care * active RA with 5 or more swollen joints * seropositive * presence of erosions * failure of methotrexate and hydroxychloroquine and sulfasalazine * failure of Leflunomide -\> or equal to 18 years * able to provide consent * able to attend usual follow up visits Exclusion Criteria: * no contraindication to etanercept or tofacitinib * active serious infection * active Tuberculosis * multiple sclerosis * current cancer * lymphoma ever * previous use of an advanced therapeutic (biologic or JAK kinase inhibitor) * less than 18 years of age * unable to provide consent
References
Publications (0)
Data not yet available
No reference posted for this study.